

## **Running Head:** Premotor cortex response to motor learning during escitalopram-intake

### **Modulation of premotor cortex response to sequence motor learning during escitalopram-intake**

Eóin N. Molloy<sup>1,2,3,4</sup>, Karsten Mueller<sup>2,5</sup>, Nathalie Beinhözl<sup>1,3</sup>, Maria Blöchl<sup>2,3,8</sup>, Fabian A. Piecha<sup>1,3</sup>, André Pampel<sup>5</sup>, Christopher J. Steele<sup>3,12</sup>, Ulrike Scharrer<sup>1,3</sup>, Gergana Zheleva<sup>1,3</sup>, Ralf Regenthal<sup>9</sup>, Bernhard Sehm<sup>3,7,13</sup>, Vadim V. Nikulin<sup>3,6</sup>, Harald E. Möller<sup>2,5</sup>, Arno Villringer<sup>2,3,4,10,11</sup> & Julia Sacher<sup>1,2,3,10</sup>

Emotion & Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences<sup>1</sup>

International Max Planck Research School NeuroCom<sup>2</sup>

Dept. of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences<sup>3</sup>

Faculty of Medicine, Leipzig University<sup>4</sup>

Nuclear Magnetic Resonance Unit, Max Planck Institute for Human Cognitive and Brain Sciences<sup>5</sup>

Centre for Cognition and Decision Making, Institute for Cognitive Neuroscience, National Research University Higher School of Economics<sup>6</sup>

Neuroplasticity & Motor Recovery Group, Max Planck Institute for Human Cognitive and Brain Sciences<sup>7</sup>

Dept. of Psychology, University of Münster<sup>8</sup>

Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, Leipzig University<sup>9</sup>

Clinic for Cognitive Neurology, Leipzig University<sup>10</sup>

Berlin School of Mind and Brain<sup>11</sup>

Dept. of Psychology, Concordia University<sup>12</sup>

Dept. of Neurology, Martin Luther University Halle-Wittenberg<sup>13</sup>

#### **Abstract:**

The contribution of selective serotonin reuptake inhibitors (SSRIs) to motor learning by inducing motor cortical plasticity remains controversial given diverse findings from positive preclinical data to negative findings in recent clinical trials. To empirically address this translational disparity, we use functional magnetic resonance imaging (fMRI) in a double-blind, randomized controlled study powered to assess whether 20 mg escitalopram improves sequence-specific motor performance and modulates cortical motor response in 64 healthy female participants. We found decreased left premotor cortex responses during sequence-specific learning performance comparing single dose and steady escitalopram state. Escitalopram plasma-levels negatively correlated with the premotor cortex response. We did not find evidence in support of improved motor performance after a week of escitalopram-intake. These findings do not support the conclusion that 1-week escitalopram intake increases motor performance but could reflect early adaptive plasticity with improved neural processing underlying similar task performance when steady peripheral escitalopram levels are reached.

**Key words:** *selective serotonin reuptake inhibitors, sequential motor learning, neural plasticity, functional MRI.*

## **Running Head:** Premotor cortex response to motor learning during escitalopram-intake

### 1 **Introduction:**

2 Motor learning is the improved performance of a motor task following practice<sup>1</sup> and is modulated  
3 by monoaminergic transmission in cortical and subcortical motor networks<sup>2,3,4</sup>. Research on this  
4 monoaminergic basis of motor learning typically focuses on dopamine signaling in both health<sup>5,6</sup>  
5 and disease<sup>7</sup>. Evidence from rodents<sup>8</sup> and stroke patients<sup>9</sup>, however, suggests that serotonin also  
6 critically modulates motor behavior. Selective serotonin reuptake inhibitors (SSRIs), commonly  
7 prescribed medications for depression and anxiety disorders<sup>10</sup>, increase extracellular serotonin and  
8 successfully treat post-stroke depression<sup>11</sup>. In the absence of depressive symptoms, several studies  
9 have also demonstrated an effect of SSRIs on the recovery of post-stroke motor dysfunction<sup>12</sup>.  
10 Notably, the FLAME trial (Fluoxetine for Motor Recovery After Acute Ischemic Stroke<sup>9</sup>) showed  
11 approximately 50% motor recovery in 57 patients following combined fluoxetine treatment and  
12 physiotherapy, in a multi-center Randomized Controlled Trial (RCT). These findings were further  
13 supported by a meta-analysis of 52 RCTs in 4,060 patients, which, however, also acknowledged  
14 heterogeneity and methodological shortcomings in a substantial proportion of trials<sup>13</sup>.

15  
16 Possible mechanisms underlying SSRI modulation of motor performance and learning include anti-  
17 inflammatory<sup>14,15</sup> and neurotrophic effects<sup>16</sup> such as increased neurogenesis<sup>17</sup>, proliferation<sup>18</sup>,  
18 protein expression enhancement<sup>19</sup>, upregulation of beta1-adrenergic receptors<sup>20</sup>, downregulation  
19 of GABA-transmission<sup>21,22</sup>, and hippocampal long-term potentiation<sup>23</sup>. These findings suggest that  
20 SSRIs may increase responsivity to environmental stimuli, possibly via changes in inhibitory and  
21 excitatory balance<sup>24</sup> and reorganization of cortical networks<sup>25-27</sup>. Studies in humans have provided  
22 support for this by demonstrating changes in resting state functional connectivity induced by a  
23 single dose of escitalopram<sup>28</sup>. Additionally, decreases in resting state alpha-frequency band induced  
24 by tryptophan depletion<sup>29</sup>, which are hypothesized to reflect alterations in the excitatory and  
25 inhibitory balance of cortical networks, have been observed in healthy volunteers. Moreover,

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

26 preliminary functional magnetic resonance imaging (fMRI) evidence has linked decreased  
27 functional responses in the motor network with improved motor performance following fluoxetine  
28 administration<sup>30-33</sup>.

29  
30 Recent large-scale RCTs in stroke patients such as the TALOS<sup>34</sup> and FOCUS trials<sup>35</sup>, involving  
31 over 642 and 3,000 patients, respectively, however, do not suggest beneficial effects of SSRIs on  
32 functional recovery. Critically, however<sup>36</sup>, these RCTs were conducted against the backdrop of  
33 routinely available rehabilitation and did not combine SSRI administration with a clearly defined  
34 motor learning paradigm, nor did they assess functional brain responses to SSRI intake. As a result,  
35 no previous study, either in healthy participants or in patients, has successfully leveraged prolonged  
36 training on an established motor learning paradigm in combination with SSRI-administration and  
37 fMRI in an adequately powered sample. Therefore, the hypothesis of whether SSRI administration,  
38 specifically in combination with an established motor learning paradigm, induces a beneficial  
39 effect on motor learning performance and changes the cortical motor response underlying the  
40 learning performance, remains to be tested empirically.

41  
42 The current study utilizes fMRI to address whether one week of SSRI administration in  
43 combination with a sequential motor learning task improves sequence specific motor performance  
44 and elicits changes in concurrent cortical motor response during task performance. In a double-  
45 blind, randomized controlled pharmacofMRI study, we administered 20 mg (to reach 80%  
46 serotonin transporter (5-HTT) occupancy)<sup>37</sup> of escitalopram, the most 5-HTT selective and rapid  
47 onset SSRI<sup>38,39</sup> or placebo, to healthy females undergoing parallel fMRI assessment and training  
48 on a variant of the sequential pinch force task (SPFT)<sup>40</sup>. We chose a healthy homogeneous and  
49 young sub-sample to avoid variance associated with pathology<sup>41,42</sup>, sex<sup>33</sup>, and age<sup>43</sup>. Our *a priori*  
50 hypotheses were (1) that one week of escitalopram intake would improve sequential motor


**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

51 performance relative to placebo, as assessed by performance in a temporal lag condition on the  
52 SPFT, calculated as the time difference between a computer controlled visual stimulus and  
53 participant control of a pinch-force device. (2) By specifying this sequence-learning condition in  
54 an fMRI contrast (hereafter referred to as the learning contrast, i.e., the difference of functional  
55 brain responses between two experimental conditions comprising two levels of task difficulty), we  
56 also hypothesized escitalopram-induced changes in fMRI-response in core components of the  
57 motor network during task performance.

## Running Head: Premotor cortex response to motor learning during escitalopram-intake

### 58 Results:

59 Following a baseline condition, participants were randomized to receive either 20 mg of  
 60 escitalopram or placebo (mannitol/aerosol) orally for 7 days. Sequence-specific motor training was  
 61 conducted 5 times; baseline, on days 1 (single dose), 5 and 6, and 7 (steady state) of escitalopram  
 62 administration. Functional MRI data were acquired at 3 concurrent time points: baseline, single  
 63 dose, and steady state (Figure 1).



64

**Figure 1. Study design and task:** Following baseline, escitalopram or placebo administration took place for 7 consecutive days. Post baseline, motor training took place at single dose (first day), days 5 and 6, and at steady state (day 7). Motor training on days 5 and 6 was completed outside the scanner. fMRI data were acquired at baseline, single dose, and steady state. Task = Sequential Pinch Force Task, fMRI = Functional Magnetic Resonance Imaging, Force = the yellow bar controlled by the participants, the rise and fall of which was required to match the rise and fall of the blue (reference bar, i.e., the bar controlled by a computer).

### 65 Demographics:

66 No differences were observed between groups in any baseline screening measures. Escitalopram  
 67 levels were within the expected range<sup>44</sup> (Table 1).

## Running Head: Premotor cortex response to motor learning during escitalopram-intake

68 **Table 1. Demographic overview:** Group demographic overview and mean single dose and steady state  
69 escitalopram plasma concentrations. Group values refer to mean±standard deviation. Demographic values rounded  
70 to the nearest whole number. Escit. = escitalopram, ASEC = antidepressant side effect checklist-score, kg/m<sup>2</sup> =  
71 kilogram force per square meter, u/l = units per liter, ng/ml = nanograms/milliliters.

	Escitalopram (n=31)	Placebo (n=33)	<i>t</i> -value	<i>p</i> -value
Age (years)	24 ± 3	23 ± 4	-0.3	0.74
BMI (kg/m <sup>2</sup> )	22 ± 2	21 ± 2	-1.3	0.19
Lutropin (u/l)	2 ± 2	1 ± 2	-1.2	0.20
Follitropin (u/l)	3 ± 3	2 ± 3	-1.3	0.19
ASEC single dose	3±3	1±1	3.9	≤0.001
ASEC steady state	1±2	1±1	-0.7	0.48
Escit. single dose (ng/ml)	20 ± 5	-	-	-
Escit. steady state (ng/ml)	46 ± 11	-	-	-

### 72 **Sequence-specific motor learning:**

73 We did not find any significant differences between the escitalopram and placebo groups on  
74 behavioral measures of sequence-specific motor learning:


75 (1) Group comparisons of mean performance at baseline did not show any significant group  
76 differences in sequence-specific motor learning behavior ( $t=-0.25$ ,  $p=0.80$ ).

77 (2) For group comparisons over time, a mixed effects model including a fixed effect of *time* fit the  
78 data significantly better than a random-intercept only model, reflecting a decrease in lag scores  
79 (Table 2). The fixed effect of *group* and the interaction of *time* and *group* did not show a significant  
80 improvement in fit, demonstrating that, while both groups improved in sequence-specific motor  
81 performance over time, they did so comparably (Figure 2).

82 (3) Post-hoc two-sample *t*-tests did not show a significant group difference in mean performance  
83 at either single dose or steady state. Comparisons of the delta scores from baseline to steady state  
84 did not show any significant differences between groups. Bayes Factor analysis of group  
85 comparisons at single dose and steady, as well as the delta, yields moderate evidence in support of  
86 the null hypothesis (Table 2).

87 (4) Additionally, correlation analyses did not show an association between total ASEC scores with  
88 mean behavioral lag scores at either single dose ( $r=-0.03$ ,  $p=0.8$ .) or at steady state ( $r=0.11$   $p=0.37$ ),  
89 respectively.

## Running Head: Premotor cortex response to motor learning during escitalopram-intake



90

**Figure 2. Sequential motor learning:** **Left:** Significant improvements in lag scores over 5 days of sequential motor training across both escitalopram and placebo. However, despite a significant learning effect, we observed no significant group differences in performance, nor did we observe an interaction effect. **Right:** Comparison of the rate of change between baseline and steady state yield no significant group differences. Bold fonts indicate training completed in the scanner.

91 **Table 2. Comparisons of nested linear mixed effects models and post-hoc testing for sequence-**  
 92 **specific lag scores:** Model comparisons for computing the omnibus tests for *group* and *time* as well as their  
 93 interaction effect for both outcome measures.  $\chi^2$  and respective *p*-values were computed from LRT between nested  
 94 models with results of independent samples *t*-tests and corresponding Bayes Factors on mean single dose, steady state,  
 95 and absolute rate of improvement scores (deltas).  $BF_{01}$  = Bayes Factor indicating the likelihood of the alternative  
 96 hypothesis compared to the null hypothesis.  $M \pm SD$  = means  $\pm$  standard deviation, LRT = likelihood ratio test, *df* =  
 97 degrees of freedom,  $\chi^2$  = Chi-square. \*Significant improvement in model fit.

Mixed Effects Modelling	Fixed Effects	Random effects	LRT		Marginal $R^2$
			$\chi^2$ (df)	<i>p</i> -value	
Intercept	-	Subject	-	-	0
Time	time	Subject	3301.3 (24)	$\leq 0.001^*$	0.2917
Group	group+time	Subject	0.0181 (1)	0.8931	0.2918
Interaction	group*time	Subject	25.722 (24)	0.3674	0.2934
Post-hoc Testing	Escitalopram $M \pm SD$	Placebo $M \pm SD$	<i>t</i> -value (df)	<i>p</i> -value	Cohen's <i>d</i> / $BF_{01}$
Single dose	99.8 $\pm$ 57.9	95.1 $\pm$ 67.8	-0.3 (62)	0.76	-0.07/0.26
Steady state	58.1 $\pm$ 36.1	63.8 $\pm$ 44.1	0.56 (62)	0.57	0.14/0.29
Delta scores	-107.1 $\pm$ 56.6	-96.7 $\pm$ 59.2	0.71 (62)	0.47	0.18/0.31

## 98 Functional MRI responses during sequence-specific motor learning:


99 (1) We did not observe any group differences in the learning contrast fMRI responses at baseline.

### Running Head: Premotor cortex response to motor learning during escitalopram-intake

100 (2) Within the escitalopram group, we found a significant decrease of the learning contrast in  
 101 bilateral motor regions (Figure 3, escitalopram panel, blue overlay) when comparing single dose  
 102 with steady state. We did not observe any significant increases in whole-brain fMRI signal for this  
 103 learning contrast.

104 (3) Comparisons of groups over time reveals decreases in the learning contrast in the left premotor  
 105 cortex of the escitalopram group between single dose and steady state that are not observed in  
 106 placebo (Figure 3, interaction panel, yellow overlay). A sensitivity analysis controlling for intra-  
 107 subject variance in task performance replicates this result, showing a significant *group* by *time*  
 108 interaction with a decrease in the learning contrast from single dose to steady state in the  
 109 escitalopram group in the left premotor cortex (Table 3).

110 (4) One-sample *t*-tests across the learning contrast images in each group at each time point show  
 111 bilateral activation in both the escitalopram and placebo groups at each of baseline, single dose,  
 112 and steady state (Figure 3).



### Figure 3. Escitalopram-induced decreases in motor responses during sequential motor learning:

Group dependent changes in the learning contrast over time. Mean functional group response of the escitalopram group (top) and placebo (bottom) at each baseline, single dose, and steady state measurements are shown in red. **Single Dose>Steady State:** Brain regions in the escitalopram group with significant decreases in the learning contrast (blue) between single dose and steady state (top) show decreases in bilateral premotor and temporal-parietal regions (Table 3). Comparisons between single dose with steady state in the placebo group yield no significant changes (bottom). **Interaction:** Comparisons of groups over time show decreases in the learning contrast signal in the left premotor cortex of the escitalopram group that are not observed in placebo (violet). Consideration of behavioral performance as a variable of interest shows brain regions where changes in the learning contrast positively correlate with improvement in motor performance, also with a peak in the left premotor cortex (overlaid in yellow). All results are shown with  $p < 0.05$  family-wise error (FWE) correction at a cluster forming threshold of  $p < 0.001$ . All orthogonal planes presented are the same.  $\beta$  = beta value at global maximum coordinate.


**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

114 **Table 3. Escitalopram-induced motor network changes in the learning contrast during sequence**  
 115 **motor learning:** Results of a paired comparison of single dose and steady state within the escitalopram group and  
 116 subsequent interaction comparisons with placebo. All results obtained with a 2x2 flexible factorial design. T=*t*-values, Z=*z*-  
 117 values, MNI(x,y,z)=MNI peak coordinates, Escit. = escitalopram group.  
 118

Brain Region	<i>p</i> (FWE-corr)	Cluster Extent	T	Z	MNI (x,y,z)
<i>Escit. Paired</i>					
Left Premotor Cortex	<0.001	913	6.33 6.25 6.17	5.50 5.44 5.39	-18, 11, 59 -21, 11, 50 -27, 8, 59
Right Premotor Cortex	<0.001	233	6.15 5.10 4.28	5.38 4.62 3.97	30, -4, 41 24, -4, 65 30, 2, 62
Left Superior Parietal Lobule	<0.001	260	5.82 5.33 5.13	5.14 4.79 4.64	-39, -46, 53 -33, -43, 32 -36, -46, 41
Left Middle Temporal Gyrus	0.025	97	4.97 3.33	4.52 3.17	-48, -58, -4 -39, -67, 8
Left Superior Frontal Gyrus	<0.001	295	4.87 4.53 4.31	4.44 4.17 4.00	-18, 35, 38 -18, 44, 20 -15, 56, 26
Right Superior Parietal Lobule	<0.001	257	4.74 4.23 4.06	4.34 3.93 3.79	12, -61, 62 18, -61, 50 33, -40, 59
Left Postcentral Gyrus	<0.001	215	4.70 4.67 3.63	4.30 4.28 3.44	-9, -46, 74 -12, 52, 65 -15, -70, 50
Right Middle Temporal Gyrus	0.002	172	4.67 3.77 3.68	4.29 3.55 3.47	42, -58, 11 33, -58, 23 27, -76, 11
<i>Interaction</i>					
Left Premotor Cortex	0.044	82	4.36 4.17 4.10	4.04 3.88 3.82	-21, 11, 50 -15, 8, 59 -18, -4, 59
<i>Interaction (Sensitivity)</i>					
Left Premotor Cortex	0.017	111	4.68 4.26 4.07	4.29 3.95 3.80	-21, 11, 50 -15, 8, 59 -27, 5, 56

## Running Head: Premotor cortex response to motor learning during escitalopram-intake

119 (5) Correlation analysis between the change in sequence-specific learning performance with the  
120 fMRI signal change in the learning contrast from single dose to steady state within the escitalopram  
121 group reveals a significant positive correlation in brain regions including the left premotor cortex  
122 (Figure 4; yellow overlay, Supplementary Table 3).  
123 (6) Correlational analysis between escitalopram plasma levels and the learning contrast in the  
124 escitalopram group shows a significant negative correlation, with increases in escitalopram plasma  
125 concentration associated with decreases in the learning contrast in the left supplementary motor  
126 area and supramarginal gyrus (Figure 4, Supplementary Table 4).



127

**Figure 4: Correlations between escitalopram plasma levels and cortical premotor response during sequence-specific learning from single dose to steady state:** (A) Escitalopram plasma concentrations negatively correlate with changes in the learning contrast in bilateral cortical motor regions, including the premotor cortex (premotor cortex from significant  $2 \times 2$  interaction overlaid in yellow), with a peak in the left supramarginal gyrus. (B) Betas containing parameter estimates for error from the left premotor cortex plotted against escitalopram plasma levels at single dose and steady state, respectively. Results refer to the sequence-specific learning contrast and are shown with  $p < 0.05$  family-wise error (FWE) correction at a cluster forming threshold of  $p < 0.001$ . Escit. = escitalopram, ng/ml = nanograms/milliliters.  $\beta$  = beta value at premotor MNI coordinates.

### 128 Analysis of mature BDNF levels:

129 Analysis of mBDNF levels from baseline to steady state in both groups combined does not reveal  
130 any significant changes over time ( $F(1, 62) = 2.195, p=0.12$ ), and paired  $t$ -tests do not indicate  
131 significant changes from baseline to steady state in either the escitalopram ( $t = -1.23, p=0.22$ ) or  
132 placebo group ( $t = -1.5, p=0.14$ ), respectively.

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

133 **Discussion:**

134 In this randomized controlled interventional study, we investigated whether administration of 20  
135 mg escitalopram improves motor learning performance and alters functional brain response in the  
136 motor network during sequence motor learning. Results show a significant learning effect in  
137 sequence-specific motor performance though this rate of improvement does not differ between  
138 groups. Additionally, we do not observe any significant group differences at any time point, or in  
139 rate of improvement. With fMRI, we find significant escitalopram-induced decreases in the left  
140 cortical premotor response during sequence-specific learning comparing single dose and steady  
141 levels of escitalopram. Moreover, consideration of behavioral performance as a variable of interest  
142 during this phase of learning reveals that these changes in the sequence-specific learning contrast  
143 positively correlate with improvement in motor performance. Finally, we observe a negative  
144 correlation between escitalopram-plasma levels and the fMRI response during the sequence-  
145 specific learning contrast in the left premotor cortex during task-performance, suggesting a parallel  
146 development between escitalopram plasma kinetics and the attenuation of cortical motor response  
147 to sequence-specific motor learning.

148  
149 The lack of an effect of SSRI-administration on motor learning performance differs from previous  
150 findings in healthy volunteers<sup>31-33</sup>. These studies, however, were neither powered nor pre-registered  
151 to test this as an *a-priori* hypothesis, with six healthy volunteers for five different behavioral tests  
152 and one fMRI experiment<sup>31,32</sup> and nineteen volunteers for six different behavioral assessments<sup>33</sup>.  
153 Additionally, we administered escitalopram, and chose a task that may be less cognitively  
154 demanding due to repetitive isotonic contractions<sup>45</sup>, possibly creating earlier ceiling effects in  
155 healthy adults. These previous findings could be specific to paroxetine, require tasks with more  
156 spatial and coordination-oriented sensorimotor components, or may only become apparent after  
157 several weeks of administration. Nevertheless, given that we administered the SSRI with the

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

158 highest transporter selectivity<sup>46</sup>, employed a task that reliably measures sequence motor learning<sup>40</sup>,  
159 and tested a well-powered sample, it is unlikely that this discrepancy is due to the choice of SSRI  
160 or motor paradigm alone. Furthermore, our exploratory analysis of mature BDNF levels in plasma  
161 did not reveal any significant changes associated with improved motor learning performance in  
162 either group. While this is consistent with findings of improved motor performance in healthy  
163 volunteers to be unrelated to peripheral BDNF levels<sup>47</sup>, evidence supportive of an association  
164 between motor skill learning and increased BDNF levels have also been reported<sup>48</sup>. While future  
165 studies should assess potential SSRI modulation of motor learning with additional paradigms, our  
166 results do not support a beneficial effect of SSRI-administration on motor learning performance in  
167 health.

168  
169 We do report evidence supportive of our second hypothesis however, with significant decreases in  
170 functional responses in left premotor cortex during sequence specific motor learning, relative to  
171 placebo (Figure 3). While both increases and decreases in functional brain responses underlie motor  
172 learning<sup>49</sup>, this pattern is dependent on differential stages of learning and is defined by multiple  
173 parallel processes<sup>50-52</sup>. Early fast learning is accompanied by rapid improvements in performance,  
174 followed by slow learning that characterizes a more consolidatory phase<sup>53,54</sup>. Patterns of functional  
175 responses observed during this phase are also influenced by the type of task, with explicit learning  
176 of repetitive and unchanging sequences hypothesized to lead to faster automation of  
177 performance<sup>51,55,56</sup> and a subsequent reduction in cognitive load needed for task completion. Given  
178 the predictable repetition of the learning sequence on our task and the timing of our assessments,  
179 it is possible that the observed escitalopram-induced decreases in the learning contrast reflect this  
180 automation of responses and subsequent consolidation of sequence learning.

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

181 Such a neural consolidation process in response to 1 week of escitalopram-intake is consistent with  
182 a recent conceptual model of SSRI influences on post-stroke recovery<sup>57</sup>. The authors propose that  
183 acute SSRI exposure changes the excitatory and inhibitory balance with increases in excitatory  
184 signaling, allowing for the remodeling of cortical pathways<sup>57</sup>. Subsequent SSRI exposure leads to  
185 a reset in homeostasis with a heightening of  $\gamma$ -aminobutyric acid (GABA) tone<sup>57</sup>, allowing for  
186 remodeled pathways to become engrained as task performance continues. Further support for this  
187 interpretation stems from studies identifying an inverse relationship between cortical GABA  
188 concentrations and functional brain responses<sup>58,59</sup> and SSRI administration has been shown to  
189 increase cortical GABA levels in rodents<sup>60</sup> and healthy volunteers<sup>61</sup>. Finally, the observation that  
190 the escitalopram-induced decrease in the learning contrast is negatively associated with  
191 escitalopram kinetics occurs in a timeframe consistent with that typically required for 5-HT<sub>1A</sub>  
192 autoreceptor desensitization<sup>62</sup>, which could also modulate effective enhancement of cortical  
193 GABAergic tone<sup>63</sup>. In summary, it is possible that this escitalopram-induced decrease in premotor  
194 response in the learning contrast reflects more effective neural task processing, relative to placebo,  
195 in a region central to temporally and visually-oriented motor learning and planning<sup>64-67</sup>. This  
196 interpretation is consistent with the hypothesis of an SSRI-induced window of experience-  
197 dependent plasticity as an attenuator of neural efficiency during performance<sup>25,26</sup>.

198  
199 An alternative explanation of this finding is a habituation effect of neural responses during  
200 repetitive sequence-specific motor learning that may be emphasized by escitalopram  
201 administration. While we report a significant three-way interaction for brain, task, and group  
202 (Figure 4), this effect is limited to the comparison between a single dose and steady state and in the  
203 escitalopram group only, despite the observation that both groups successfully improve  
204 performance over time. It is possible that the neural responses during task performance in the  
205 placebo group reflects a simpler order effect, whereby neural responses adapt incrementally, rather

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

206 than via an adaptive plasticity mechanism. Integration of more direct measures of cortical  
207 excitation and inhibition can allow for more fine-grained investigations into acute and subacute  
208 SSRI-effects.

209

210 Nevertheless, there are some limitations to consider when interpreting these results. We  
211 acknowledge that the initial strong learning effect may have masked more subtle modulation of  
212 performance with escitalopram at a later training session. Though a known limitation of this task,  
213 we chose the SPFT for this well-established and reliable learning effect. While performance  
214 reaches a ceiling during the fourth and fifth sessions, as described previously<sup>40</sup>, we still observe a  
215 considerable change in performance after the administration of the single dose and subsequent  
216 training sessions, thus maintaining the falsifiability of our primary hypothesis. Second, our results  
217 may not generalize to males or older adults as our sub-sample consists only of females with  
218 standardized downregulation of ovarian hormones. This was a deliberate *a-priori* restriction to  
219 eliminate confounds such as sex-differences<sup>33</sup> and fluctuating endogenous hormones<sup>68</sup> on  
220 environmental learning and escitalopram responsivity. Third, other studies have gradually  
221 increased escitalopram doses for pharmaco-fMRI protocols in healthy participants<sup>69</sup> to minimize  
222 adverse effects. We chose a fixed dose of 20 mg to reliably block 80 % of 5-HTT<sup>37</sup>, an approach  
223 previously well tolerated<sup>28</sup>. While four participants discontinued protocol because of adverse  
224 effects in the escitalopram group, this was also the case for two placebo participants, and there was  
225 no group difference in self-reported side effects at steady state. Finally, fMRI provides an indirect  
226 measure of neural activity, which is susceptible to non-neural changes such as vascular uncoupling.  
227 Given the functional specificity of the premotor cortex, it is unlikely that these findings are solely  
228 driven by changes in global blood flow. We cannot, however, identify underlying molecular  
229 mechanisms, which require quantitative measures such as MR-spectroscopy measures of GABA

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

230 and glutamate or [<sup>11</sup>C]UCB-J positron emission tomography, a recently developed technique for *in*  
231 *vivo* imaging of synaptic plasticity<sup>70,71</sup>.

232

233 In conclusion, this is the first study to investigate the effect of steady escitalopram administration  
234 on motor learning in an established sequential motor learning paradigm and the associated brain  
235 response in a sufficiently powered sample. In this pre-registered, randomized, controlled,  
236 interventional study, we do not find evidence in support of improved performance in response to 1  
237 week of escitalopram-intake during sequence-specific motor training. A major difference we  
238 observe between groups is a decrease in premotor cortical responses during sequence-specific  
239 learning performance contrasting single dose and steady drug state. Considering previous findings  
240 on sequential motor learning and associated neural correlates in the motor network, less premotor  
241 response during similar performance may suggest more effective neural processing and greater  
242 consolidation of performance<sup>64</sup>. By combining escitalopram administration and sequence-specific  
243 motor training for one week, we provide the first empirically tested framework for assessing SSRI-  
244 effects on human adaptive motor plasticity in health. Our paradigm and findings may help  
245 disentangle the seemingly contradictory results between preclinical models and recent clinical trials  
246 and represent an important milestone towards understanding the role of SSRIs in human motor  
247 learning.

## **Running Head:** Premotor cortex response to motor learning during escitalopram-intake

### 248 **Materials and methods:**

#### 249 **Participants & eligibility:**

250 The study was designed to have statistical power of 95% to detect a significant effect of  
251 escitalopram on sequence motor learning, assuming a small effect size ( $d=0.20$ ) and an  $\alpha$ -level of  
252  $<0.05$ . A power analysis conducted using G\*Power (v.3.1.9.2)<sup>72</sup> suggested a minimum sample size  
253 of 56. Eligible individuals were right-handed, aged 18–35 years, with a body mass index (BMI)  
254 18.5-25 kg/m<sup>2</sup>, without history of neurological or psychiatric illness, and female on oral  
255 contraceptives for  $\leq 3$  months<sup>73,74</sup> to eliminate sex and hormone-dependent escitalopram  
256 responsivity<sup>75</sup>. Exclusion criteria were medication use, contraindications for MRI, tobacco use,  
257 alcohol abuse, positive drug or pregnancy tests, professional musicianship and athleticism, and  
258 abnormal QT times in electrocardiogram screenings. In total, 88 participants were screened with  
259 71 enrolled. Analyses included 64 volunteers for the behavioral analysis as 6 (escitalopram=4)  
260 chose to discontinue participation and n=1 (placebo) was excluded due to a pre-analytical error in  
261 plasma sample acquisition. Sixty volunteers were included in functional imaging analysis as 4 were  
262 excluded due to MRI data quality concerns (2 escitalopram) due to head movement. 1 volunteer  
263 from the placebo group was excluded due to an artefact in an anatomical sequence and 1 participant  
264 from the escitalopram group was excluded due to an artefact detected during acquisition of the  
265 functional sequence (Supplementary Figure 1).

#### 266 **Study design and procedure:**

267 The Ethics committee of the Faculty of Medicine, Leipzig University approved all procedures  
268 (approval number 390/16-ek) and the study was pre-registered at clinicaltrials.gov (ID:  
269 NCT03162185). Participants were randomized to receive either 20 mg of escitalopram or placebo  
270 (mannitol/aerosol) orally for 7 days. Randomization was performed by the Central Pharmacy of  
271 Leipzig University with equal condition allocation. Sequential motor training was conducted 5  
272 times (baseline, on day 1 of escitalopram administration, days 5 and 6 of drug administration, and

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

273 at steady state – after 7 days). Functional magnetic resonance imaging data (fMRI) and serum  
274 mature brain-derived neurotrophic factor (mBDNF) samples were acquired at baseline, single dose,  
275 and steady state. Electrocardiogram recordings were conducted at single dose, day 4, and steady  
276 state to monitor potential changes in QT intervals. Adverse reactions to escitalopram were recorded  
277 using the antidepressant side-effects checklist (ASEC)<sup>76</sup>. All participants remained under medical  
278 supervision during the experiment. Concentrations of escitalopram in plasma was assessed  
279 chromatographically using a quality control sample. Deviation of the measured escitalopram  
280 concentration of the sample was tested for an acceptance interval of  $\pm 15\%$ . All behavioral and  
281 fMRI assessments took place 3 hours after escitalopram or placebo intake to allow for escitalopram  
282 to reach maximum levels in serum<sup>44</sup>.

283 **Sequential pinch force task:**

284 We assessed sequence motor learning using a variant of the sequential pinch force task (SPFT),  
285 with Presentation (v16.5) running on WindowsXP. Baseline, single dose, and steady state  
286 measurements took place during fMRI, while day 5 and day 6 were conducted outside the scanner  
287 on an identical separate device. Task completion involved controlling the rise and fall of a yellow  
288 bar (force) via the participant's thumb and index finger (attenuated to individual strength) while  
289 attempting to match the speed of a moving computer controlled blue reference bar (Figure 1). We  
290 measured performance in two conditions: (1) a control condition, where the reference bar moves  
291 sinusoidally and (2) a sequence-specific learning condition, in which the reference moves in a  
292 sequential pattern that remains stable across sessions. A rest condition punctuated training to avoid  
293 fatigue. Each session consisted of 5 blocks with 3 trials per block and cycled through simple, rest,  
294 and learning. Participants received no feedback regarding performance. To assess performance, we  
295 calculated the time difference (lag) in milliseconds between the reference and force bar during the  
296 learning trials.

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

297 **Demographic data analysis:**

298 Independent samples *t*-tests using the R statistical programming language<sup>77</sup> tested for potential  
299 group differences in age, BMI, downregulated hormonal profile, and on total ASEC scores at single  
300 dose and steady state.

301 **Behavioral data preprocessing:**

302 All SPFT data were preprocessed using in house Matlab scripts. Quality control used an outlier  
303 labeling approach<sup>78</sup> implemented in Python (v2.7.15) in which trial, condition, group, and outcome  
304 specific interquartile ranges were multiplied by a factor of 1.5 to compute upper and lower bound  
305 thresholds.

306 **Behavioral data analysis:**

307 All behavioral data analyses were conducted using R.

308 (1) Independent samples *t*-tests assessed baseline group differences using the ‘t.test’ function to  
309 assess efficacy of randomization.

310 (2) Comparisons between groups over time employed an omnibus linear random-intercept mixed  
311 effect modeling approach using the ‘lmer’ function, within the ‘lme4’ package in R (independent  
312 factors: *group*, *time*, dependent variable: *lag*). Contributions of each fixed effects were assessed  
313 with a likelihood ratio test for improvement of model fit.

314 (3) Post-hoc independent samples *t*-tests were conducted on mean single dose and steady state  
315 scores to assess potential group differences at each critical time point of escitalopram-  
316 administration. Additionally, the delta (difference between mean performance at steady state  
317 compared to baseline) was compared between groups for each outcome via independent samples

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

318 *t*-tests. Bayes Factor *t*-tests using the ‘ttestBF’ function in the ‘BayesFactor’ package assessed the  
319 likelihood of the null hypothesis for all independent sample analyses.

320 (4) Pearson’s correlation analyses assessed potential associations between total ASEC scores and  
321 mean lag performance at both single dose and steady state.

322 **fMRI data acquisition:**

323 fMRI data were acquired with gradient-echo echo planar imaging (EPI) on a 3-Tesla MAGNETOM  
324 Verio scanner (Siemens, Erlangen, Germany, 32-channel head-coil, flip angle 90°, TR=2000 ms,  
325 TE=30 ms, field of view=192×192 mm<sup>2</sup>, 30 slices, 64×64 matrix, 3×3×3mm<sup>3</sup> nominal resolution,  
326 495 volumes, aligned -15° along the anterior to posterior commissure, ~16 minutes). A whole-  
327 brain three dimensional T1-weighted Magnetization Prepared Rapid Gradient-echo (MPRAGE)  
328 was also acquired at each time point for co-registration<sup>79</sup> with inversion time, TI=900 ms, TR=2300  
329 ms, TE=2.98 ms, 1×1×1mm<sup>3</sup> nominal isotropic resolution, ~9 minutes<sup>80</sup>.

330 **fMRI data analysis – Preprocessing and first-level analysis:**

331 Data pre-processing was conducted using SPM12 (v12.7219). Data were realigned, unwarped,  
332 normalized to Montréal Neurological Institute (MNI) space, and smoothed with a Gaussian kernel  
333 (8mm at full-width-half-maximum). First level analysis was performed for baseline, single dose  
334 and steady state separately using a general linear model (GLM) including all three experimental  
335 conditions: learning, simple, and rest. In addition, each analysis contained head-movement  
336 parameters obtained during preprocessing motion correction. Following parameter estimation, we  
337 generated contrast images specific to sequence learning by specifying the learning contrast (i.e.,  
338 the difference between the learning and simple conditions).

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

339 **fMRI data analysis – Group-level analysis:**

340 Using contrast images obtained at the first level, second level analyses were performed with  
341 SPM12 in Matlab (v9.7). Results were considered statistically significant at a cluster-defining  
342 threshold of  $p < 0.001$  corrected at  $p < 0.05$  using family-wise error (FWE) for multiple comparisons  
343 at the cluster-level.

344 (1) An independent-samples  $t$ -test assessed potential differences in the learning contrast between  
345 groups at baseline.

346 (2) Following baseline comparisons, we assessed changes across time within the escitalopram  
347 group. Using a paired  $t$ -test, we each compared baseline to single dose, baseline to steady state, and  
348 single dose to steady state. Both directions of each  $t$ -statistic were assessed to test for both increases  
349 and decreases in fMRI response during the learning contrast over time.

350 (3) To investigate group differences with respect to results obtained in analyses (2), we specified a  
351 flexible factorial model using factors for *subject* (for repeated measurements), *time* and *group*.  
352 Comparisons from (2) yielding a significant difference were repeated within this model to validate  
353 results from paired  $t$ -tests. Within this model, we tested for an interaction between *group* and *time*.  
354 Additionally, a sensitivity analysis repeated this interaction analysis with an additional regressor.  
355 Two mean behavioral measures for each participant (one for each timepoint) were entered as  
356 nuisance covariates in the GLM<sup>81</sup>. For these behavioral measures, we used the behavioral  
357 sequence-specific learning measure “lag learning-simple score” (LLSS), as calculated for each  
358 participant by subtracting the mean simple condition scores from the mean learning condition lag  
359 scores.

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

360 (4) To visualize mean signal for the learning contrast for each group at baseline, single dose, and  
361 steady state, a series of one-sample *t*-tests was conducted on each group at each timepoint  
362 separately.

363 (5) In order to test for a correlation between motor performance improvement and change in the  
364 learning contrast within the escitalopram group, we used the LLSS as an effect of interest within a  
365 second flexible factorial design<sup>81</sup>. Here, the model was generated using the factors *subject*, *group*,  
366 and *LLSS*.

367 (6) With the aim of testing for a correlation between escitalopram plasma and brain kinetics during  
368 the learning contrast, escitalopram plasma levels were entered as an effect of interest within a third  
369 flexible factorial design<sup>81</sup>, within the escitalopram group, using the factors *subject*, *group*, and  
370 *plasma escitalopram levels*.

371 **Analysis of serum mature BDNF levels:**

372 A one-way repeated measures ANOVA was implemented in R using the ‘Anova’ function to assess  
373 changes in serum mBDNF levels across time. Paired samples *t*-tests in both the escitalopram and  
374 placebo groups compared baseline to steady state within each group, separately.

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

**Acknowledgements:**

We thank Heike Schmidt-Duderstedt and Kerstin Flake for assisting with preparation of the figures and Dr. Kristin Ihle for her assistance with medical supervision of all participants during the experiments.

**Competing Interests:**

The authors declare that no competing interests exist.

**Funding:**

This research was supported by the FAZIT Foundation to ENM and The Branco Weiss Fellowship – Society in Science to JS and the Max Planck Society.

## Running Head: Premotor cortex response to motor learning during escitalopram-intake

### References:

1. Diedrichsen, J., Kornysheva, K. (2015). Motor skill learning between selection and execution. *Trends Cogn Sci.* 19(4):227-33. doi: 10.1016/j.tics.2015.02.003.
2. Molina-Luna K., Pekanovic, A., Röhrich, S., Hertler, B., Schubring-Giese, M., Rioult-Pedotti, MS., Luft, A.R. (2009). Dopamine in motor cortex is necessary for skill learning and synaptic plasticity. *PLoS One.* 17;4(9):e7082. doi:10.1371/journal.pone.0007082.
3. Rioult-Pedotti, MS., Pekanovic, A., Atiemo, CO., Marshall, J., Luft, AR. (2015). Dopamine Promotes Motor Cortex Plasticity and Motor Skill Learning via PLC Activation. *PLoS One.* 10(5):e0124986. doi: 10.1371/journal.pone.0124986.
4. Vitrac, C., Benoit-Marand, M. (2017) Monoaminergic Modulation of Motor Cortex Function. *Front. Neural Circuits* 11:72. doi: 10.3389/fncir.2017.00072.
5. Flöel, A., Breitenstein, C., Hummel, F., Celnik, P., Gingert, C., Sawaki, L., Knecht, S., Cohen, LG. (2005). Dopaminergic influences on formation of a motor memory. *Ann Neurol.* 58(1):121-30. doi:10.1002/ana.20536.
6. Flöel, A., Garraux, G., Xu, B., Breitenstein, C., Knecht, S., Herscovitch, P., Cohen, LG. (2008). Levodopa increases memory encoding and dopamine release in the striatum in the elderly. *Neurobiol Aging.* 29(2):267-79. doi:10.1016/j.neurobiolaging.2006.10.009
7. Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., Tamburin, S. (2016). Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. *Parkinsons Dis.* doi:10.1155/2016/9832839
8. Maya Vetencourt, JF., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., O'Leary, OF., Castrén, E., Maffei, L. (2008). The antidepressant fluoxetine restores plasticity in the adult visual cortex. *Science*, 320(5874), 385-388. doi:10.1126/science.1150516.
9. Chollet, F., Tardy, J., Albucher, JF., Thalamas, C., Berard, E., Lamy, C., Bejot, Y., Deltour, S., Jaillard, A., Niclot, P., Guillon, B., Moulin, T., Marque, P., Pariente J, Arnaud, C. Loubinoux, I. (2011). Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. *Lancet Neurol*, 10(2), 123-130. doi:10.1016/S1474-4422(10)70314-8.
10. Cipriani, A., Furukawa, TA., Salanti, G., Chaimani, A., Atkinson, LZ., Ogawa, Y., Leucht, S., Ruhe, HG., Turner, EH., Higgins, JPT., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, JPA., Geddes, JR. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet.* 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7.
11. Hackett, ML., Anderson, CS., House, A., Halteh, C. (2006). Interventions for preventing depression after stroke. *Cochrane Database Syst Rev.* 16;(3):CD003689. doi: 10.1002/14651858.CD003689.pub3.

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

12. Acler, M., Robol, E., Fiaschi, A., Manganotti, P. (2009). A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. *Journal of Neurology* 256(7):1152-8. doi: 10.1007/s00415-009-5093-7.
13. Mead, GE., Hsieh, CF., Hackett, M. (2013). Selective serotonin reuptake inhibitors for stroke recovery. *JAMA*. 310(10):1066-7. doi: 10.1001/jama.2013.107828.
14. Lim, CM., Kim, SW., Park, JY., Kim, C., Yoon, SH., Lee, JK. (2009). Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. *J Neurosci Res*. 87(4):1037-45. doi: 10.1002/jnr.21899.
15. Tynan, RJ., Weidenhofer, J., Hinwood, M., Cairns, MJ., Day, TA., Walker, FR. (2012). A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. *Brain Behav Immun*. 26(3):469-79. doi: 10.1016/j.bbi.2011.12.011.
16. Schmidt, HD., Duman, RS. (2007). The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. *Behav Pharmacol*. 18(5-6):391-418. doi: 10.1097/FBP.0b013e3282ee2aa8
17. Malberg, JE., Eisch, AJ., Nestler, EJ., Duman, RS. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J Neurosci*. 15;20(24):9104-10. doi: <https://doi.org/10.1523/JNEUROSCI.20-24-09104.2000>.
18. Lyons, L., ElBeltagy, M., Umka, J., Markwick, R., Startin, C., Bennett, G., Wigmore, P. (2011). Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. *Psychopharmacology (Berl)*. 215(1):105-15. doi: 10.1007/s00213-010-2122-2.
19. Cooke, JD., Grover, LM., Spangler, PR. (2009). Venlafaxine treatment stimulates expression of brain-derived neurotrophic factor protein in frontal cortex and inhibits long-term potentiation in hippocampus. *Neuroscience*. 162(4):1411-9. doi: 10.1016/j.neuroscience.2009.05.037.
20. Pälvimäki, EP., Laakso, A., Kuoppamäki, M., Syvälahti, E., Hietala, J. (1994). Up-regulation of  $\beta$ 1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. *Psychopharmacology*. 115: 543. <https://doi.org/10.1007/BF02245579>
21. Yan, Z. (2002). Regulation of GABAergic inhibition by serotonin signalling in prefrontal cortex. *Molecular Neurobiology* 26(2-3) 203-216. doi: 10.1385/MN:26:2-3:203
22. Choi, HC., Kim, YI., Song, HK., Kim, JE., Kim, DS., Kang, TC. (2010). Effects of selective serotonin reuptake inhibitors on GABAergic inhibition in the hippocampus of normal and pilocarpine induced epileptic rats. *Brain Res*. 1357:131-41. doi: 10.1016/j.brainres.2010.08.010.

## **Running Head:** Premotor cortex response to motor learning during escitalopram-intake

23. Mlinar, B., Stocca, G., Corradetti, R. (2015). Endogenous serotonin facilitates hippocampal long-term potentiation at CA3/CA1 synapses. *J Neural Transm(Vienna)*. 122(2):177-85. doi: 10.1007/s00702-014-1246-7.
24. Batsikadze, G., Paulus, W., Kuo, MF., Nitsche, MA. (2013). Effect of serotonin on paired associative stimulation-induced plasticity in the human motor cortex. *Neuropsychopharmacology*, 38(11), 2260-2267. doi:10.1038/npp.2013.127.
25. Castrén, E. (2005). Is mood chemistry? *Nat Rev Neurosci*, 6(3), 241-246. doi:10.1038/nrn1629
26. Castrén, E. (2013). Neuronal network plasticity and recovery from depression. *JAMA Psychiatry*, 70(9), 983-989. doi:10.1001/jamapsychiatry.2013.1
27. Siepmann, T., Penzlin, A.I., Kepplinger, J., Illigens, BM., Weidner, K., Reichmann, H., Barlind, K. (2015). Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. *Brain Behav*. 23;5(10): e00373. doi: 10.1002/brb3.373.
28. Schaefer, A., Burmann, I., Regenthal, R., Arélin, K., Barth, C., Pampel, A., Villringer, A., Margulies, DS., Sacher, J. (2014). Serotonergic modulation of intrinsic functional connectivity. *Current Biology*, 24(19), 2314-2318. doi: 10.1016/j.cub.2014.08.024.
29. Knott, VJ., Howson, AL., Perugini, M., Ravindran, AV., & Young, SN. (1999). The Effect of Acute Tryptophan Depletion and Fenfluramine on Quantitative EEG and Mood in Healthy Male Subjects. *Biological Psychiatry*; (46) 229–238.
30. Loubinoux, I., Boulanouar, K., Ranjeva, JP., Carel, C., Berry, I., Rascol, O., Celsis, P., Chollet, F. (1999). Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. *J Cereb Blood Flow Metab*. 19(12):1365-75. doi: 10.1097/00004647-199912000-00010
31. Loubinoux, I., Pariente, J., Boulanouar, K., Carel, C., Manelfe, C., Rascol, O., Celsis, P., Chollet, F. (2002a). A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. *Neuroimage*, 15(1), 26-36. doi:10.1006/nimg.2001.0957.
32. Loubinoux, I., Pariente, J., Rascol, O., Celsis, P., Chollet, F. (2002b). Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects. *Neuropsychologia*. 40(11):1815-21.
33. Loubinoux, I., Tombari, D., Pariente, J., Gerdelat-Mas, A., Franceries, X., Cassol, E., Rascol, O., Pastor, J., Chollet, F. (2005). Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. *Neuroimage*. 27(2):299-313. doi:10.1016/j.neuroimage.2004.12.023
34. Kraglund, KL., Mortensen, JK., Damsbo, AG., Modrau, B., Simonsen, SA., Iversen, HK., Madsen, M., Grove, EL., Johnsen, SP., Andersen, G. (2018). Neuroregeneration and

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS). *Stroke*. 49(11):2568-2576. doi:10.1161/STROKEAHA.117.020067.

35. FOCUS Trial Collaboration. (2019). Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. *Lancet*. 393(10168):265-274. doi: 10.1016/S0140-6736(18)32823-X.
36. van der Worp, BH. (2019). Fluoxetine and recovery after stroke. *Lancet*. 393(10168):206-207. doi: 10.1016/S0140-6736(18)32983-0.
37. Klein, N., Sacher, J., Geiss-Granadia, T., Attarbaschi, T., Mossaheb, N., Lanzenberger, R., Pötzi, C., Holik, A., Spindelegger, C., Asenbaum, S., Dudczak, R., Tauscher, J., Kasper S. (2006). In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. *Psychopharmacology (Berl)*. 188(3):263-72. doi:10.1007/s00213-006-0486-0.
38. Kasper, S., Spadone C., Verpillat P., Angst J. (2006). Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. *Int Clin Psychopharmacol*. 21(2):105-10.
39. Sanchez, C., Reines, EH., Montgomery, SA. (2014). A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? *Int Clin Psychopharmacol*. 29(4):185-96. doi: 10.1097/YIC.0000000000000023.
40. Gryga, M., Taubert, M., Dukart, J., Vollmann, H., Conde, V., Sehm, B., Villringer, A., Ragert, P. (2012). Bidirectional gray matter changes after complex motor skill learning. *Front Syst Neurosci*, 6:37. doi:10.3389/fnsys.2012.00037
41. Pasqualetti G., Gori G., Blandizzi C., Del Tacca, M. (2010). Healthy volunteers and early phases of clinical experimentation. *Eur J Clin Pharmacol*.;66(7):647-53. doi: 10.1007/s00228-010-0827-0.
42. Karakunnel, JJ., Bui, N., Palaniappan, L., Schmidt, KT., Mahaffey, KW., Morrison, B., Figg., WD., Kummar, S. (2018). Reviewing the role of healthy volunteer studies in drug development. *J Transl Med*. 4;16(1):336. doi: 10.1186/s12967-018-1710-5.
43. van Dyck, CH., Malison, RT., Seibyl, JP., Laruelle, M., Klumpp, H., Zoghbi, SS., Baldwin, RM., Innis, RB. (2000) Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. *Neurobiol Aging*. 21(4):497-501. doi: 10.1016/s0197-4580(00)00152-4.
44. Rao, N. (2007). The Clinical Pharmacokinetics of Escitalopram. *Clinical Pharmacokinetics* 46(4):281-90. DOI: 10.2165/00003088-200746040-00002.
45. Hardwick, RM., Rottschy, C., Miall, RC., Eickhoff, SB. (2013). A quantitative meta-analysis and review of motor learning in the human brain. *Neuroimage*. 15; 67:283-97. doi: 10.1016/j.neuroimage.2012.11.020.

## Running Head: Premotor cortex response to motor learning during escitalopram-intake

46. Owens, MJ., Knight, DL., Nemeroff, CB. (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. *Biol Psychiatry*. 50(5):345-50. doi: 10.1016/s0006-3223(01)01145-3
47. Baird, JF., Gaughan, ME., Saffer, HM., Sarzynski, MA., Herter, TM., Fritz, SL., den Ouden, DB., Stewart, J.C. (2018). The effect of energy-matched exercise intensity on brain-derived neurotrophic factor and motor learning. *Neurobiol Learn Mem*. 156:33-44. doi: 10.1016/j.nlm.2018.10.008.
48. Grégoire, CA., Berryman, N., St-Onge, F., Vu, TTM., Bosquet, L., Arbour, N., Bherer, L. (2019). Gross Motor Skills Training Leads to Increased Brain-Derived Neurotrophic Factor Levels in Healthy Older Adults: A Pilot Study. *Front Physiol*. 10: 410. doi:10.3389/fphys.2019.00410.
49. Wymbs, FN., & Grafton, ST. (2014). The Human Motor System Supports Sequence-Specific Representations over Multiple Training-Dependent Timescales. *Cerebral Cortex*, 25(11) 4213–4225, doi: <https://doi.org/10.1093/cercor/bhu144>
50. Penhune, VB., Steele, CJ. (2012). Parallel contributions of cerebellar, striatal and M1 mechanisms to motor sequence learning. *Behav Brain Res*. 15;226(2):579-91. doi: 10.1016/j.bbr.2011.09.044.
51. Toni, I., Krams, M., Turner, R., Passingham, RE. (1998). The time course of changes during motor sequence learning: a whole-brain fMRI study. *Neuroimage*. 8(1):50-61. doi:<https://doi.org/10.1006/nimg.1998.0349>
52. Luft, AR., Buitrago, MM. (2005). Stages of motor skill learning. *Mol Neurobiol* 32(3):205-16. doi:10.1385/MN:32:3:205.
53. Karni, A., Meyer, G., Rey-Hipolito, C., Jezzard, P., Adams, MM., Turner, R., Ungerleider, LG. (1998). The acquisition of skilled motor performance: fast and slow experience-driven changes in primary motor cortex. *PNAS*;3;95(3):861-8. doi: 10.1073/pnas.95.3.861.
54. Hotermans, C., Peigneux, P., Maertens de Noordhout, A., Moonen, G., Maquet, P. (2006). Early boost and slow consolidation in motor skill learning. *Learn Mem*.;13(5):580-3. doi:10.1101/lm.239406
55. Poldrack, RA., Sabb, FW., Foerde, K., Tom, SM., Asarnow, RF., Bookheimer, SY., Knowlton, BJ. (2005). The neural correlates of motor skill automaticity. *J Neurosci*. 25(22):5356-64. doi: <https://doi.org/10.1523/JNEUROSCI.3880-04.2005>
56. Yang, J. (2015). The influence of motor expertise on the brain activity of motor task performance: A meta-analysis of functional magnetic resonance imaging studies. *Cogn Affect Behav Neurosci*. 15(2):381-94. doi: 10.3758/s13415-014-0329-0.
57. Schneider CL, Majewska AK, Busza A, Williams ZR, Mahon BZ, Sahin B. (2019). Selective serotonin reuptake inhibitors for functional recovery after stroke: Similarities with the critical period and the role of experience-dependent plasticity. *J Neurol*. 1-7. doi: 10.1007/s00415-019-09480-0

## Running Head: Premotor cortex response to motor learning during escitalopram-intake

58. Stagg, C.J., Bachtiar, V., Johansen-Berg, H. (2011). The role of GABA in human motor learning. *Curr Biol.* 21(6):480-4. doi: 10.1016/j.cub.2011.01.069.
59. Stagg, C.J., Bachtiar, V., Amadi, U., Gudberg, C.A., Ilie, A.S., Sampaio-Baptista, C., O'Shea, J., Woolrich, M., Smith, S.M., Filippini, N., Near, J., Johansen-Berg H. (2014). Local GABA concentration is related to network-level resting functional connectivity. *Elife.* 25;3:e01465. doi: 10.7554/eLife.01465.
60. Chen, Z., Silva, A.C., Yang, J., Shen, J. (2005). Elevated endogenous GABA level correlates with decreased fMRI signals in the rat brain during acute inhibition of GABA transaminase. *J Neurosci Res.* 79(3):383-91.
61. Bhagwagar, Z., Wylezinska, M., Taylor, M., Jezzard, P., Matthews, P.M., Cowen, P.J. (2004). Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. *Am J Psychiatry.* 161(2):368-70. doi: 10.1176/appi.ajp.161.2.368
62. El Mansari, M., Sánchez, C., Chouvet, G., Renaud, B., Haddjeri, N. (2005). Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. *Neuropsychopharmacology.* 30(7):1269-77. doi:10.1038/sj.npp.1300686
63. Lladó-Pelfort, L., Santana, N., Ghisi, V., Artigas, F., Celada, P. (2012). 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. *Cereb Cortex.* 22(7):1487-97. doi: 10.1093/cercor/bhr220.
64. Karim, H.T., Huppert, T.J., Erickson, K.I., Wollam, M.E., Sparto, P.J., Sejdić, E., Van Swearingen, J.M. (2017). Motor sequence learning-induced neural efficiency in functional brain connectivity. *Behav Brain Res.* 15;319:87-95. doi: 10.1016/j.bbr.2016.11.021.
65. Mushiake, H., Inase, M., Tanji, J. (1991). Neuronal activity in the primate premotor, supplementary, and precentral motor cortex during visually guided and internally determined sequential movements. *J Neurophysiol*;66(3):705-18.
66. Halsband, U., Ito, N., Tanji, J., Freund, H.J. (1993). The role of premotor cortex and the supplementary motor area in the temporal control of movement in man. *Brain*;116 (Pt 1):243-66. doi:10.1093/brain/116.1.243.
67. Kalaska, J.F., Crammond, D.J. (1995). Deciding not to GO: neuronal correlates of response selection in a GO/NOGO task in primate premotor and parietal cortex. *Cereb Cortex*.;5(5):410-28. doi:10.1093/cercor/5.5.410.
68. Bianchini, F., Verde, P., Colangeli, S., Boccia, M., Strollo, F., Guariglia, C., Bizzarro, G., Piccardi, L. (2018). Effects of oral contraceptives and natural menstrual cycling on environmental learning. *BMC Womens Health.* 18(1):179. doi: 10.1186/s12905-018-0671- 4.
69. Henry, M.E., Lauriat, T.L., Lowen, S.B., Churchill, J.H., Hodgkinson, C.A., Goldman, D., Renshaw, P.F. (2013). Effects of citalopram and escitalopram on fMRI response to

## Running Head: Premotor cortex response to motor learning during escitalopram-intake

- affective stimuli in healthy volunteers selected by serotonin transporter genotype. *Psychiatry Res.* 213(3): 217–224. doi:10.1016/j.psychres.2013.05.008.
70. Finnema, S.J., Nabulsi, N.B., Eid, T., Detyniecki, K., Lin, S.F., Chen, M.K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., Spencer, D.D., Mercier, J., Hannestad, J., Huang, Y., Carson, R.E. Imaging synaptic density in the living human brain. *Sci Transl Med.* 8(348):348ra96. doi: 10.1126/scitranslmed.aaf6667.
71. Chen, M.K., Mecca, A.P., Naganawa, M., Finnema, S.J., Toyonaga, T., Lin, S.F., Najafzadeh, S., Ropchan, J., Lu, Y., McDonald, J.W., Michalak, H.R., Nabulsi, N.B., Arnsten, A.F.T., Huang, Y., Carson, R.E., van Dyck, C.H. (2018). Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. *JAMA Neurol.* 75(10):1215-1224. doi: 10.1001/jamaneurol.2018.1836.
72. Faul, F., Erdfelder, E., Lang, A.G., Buchner, A. (2007). G\*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods.* 39(2):175-91. doi:10.3758/bf03193146.
73. Hampson, E. & Kimura D. (1988). Reciprocal effects of hormonal fluctuations on human motor and perceptual-spatial skills. *Behav Neurosci.* 102(3):456-9. doi:10.1037//0735-7044.102.3.456
74. Barth, C., Villringer, A., Sacher, J. (2015). Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. *Front Neurosci.* 9:37. doi: 10.3389/fnins.2015.00037.
75. LeGates, T., Kvarita, M.D., Thompson, S.M. (2019). Sex differences in antidepressant efficacy. *Neuropsychopharmacology*;44(1):140-154. doi: 10.1038/s41386-018-0156-z.
76. Uher, R., Farmer, A., Henigsberg, N., Rietschel, M., Mors, O., Maier, W., Kozel, D., Hauser, J., Souery, D., Placentino, A., Strohmaier, J., Perroud, N., Zobel, A., Rajewska-Rager, A., Dernovsek, M.Z., Larsen, E.R., Kalember, P., Giovannini, C., Barreto, M., McGuffin, P., Aitchison, K.J. (2009). Adverse reactions to antidepressants. *Br J Psychiatry.* 195(3):202-10. doi: 10.1192/bjp.bp.108.061960.
77. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
78. Iglewicz, B., Banerjee, S. (2001). A simple univariate outlier identification procedure. Proceedings of the Annual Meeting of the American Statistical Association.
79. Mugler, J.P., 3rd, Brookeman, J.R. (1990). Three-dimensional magnetization-prepared rapid gradient-echo imaging (3D MP RAGE). *Magn Reson Med*;15(1):152-157. doi: 10.1002/mrm.1910150117.
80. Streitbürger, D.P., Pampel, A., Krueger, G., Lepsien, J., Schroeter, M.L., Mueller, K., Möller, H.E. (2014). Impact of image acquisition on voxel-based-morphometry investigations


**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

of age-related structural brain changes. *Neuroimage*. 15; 87:170-82.  
doi:10.1016/j.neuroimage.2013.10.051.

81. Holiga, Š., Mueller, K., Möller, HE., Sieger, T., Schroeter, ML., Vymazal, J. (2013). Motor matters: tackling heterogeneity of Parkinson's disease in functional MRI studies. *PLoS One*. 2013;8:e56133. doi.org/10.1371/journal.pone.0056133.

## Running Head: Premotor cortex response to motor learning during escitalopram-intake

### (i) Supplementary Methods:



**Supplementary Figure 1. Overview of study work-flow:** This flow chart details the screening, inclusion, randomization, and exclusion procedure. Six participants did not complete the study protocol due to self-reported adverse effects (Placebo = 2/escitalopram = 4). Two participants who completed the protocol (Placebo = 1, SSRI = 1) were excluded due to excess head movement as calculated by framewise displacement ( $>3SD$  outside the mean), the presence of structural (placebo  $n=1$ ) and functional (escitalopram  $n=1$ ) image artifacts, and a pre-analytical error in plasma acquisition ( $n=1$ \*). \*Refers to the same participant excluded from both behavioral and fMRI analyses.

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

**(ii) Supplementary Results**

**Supplementary Table 1. Mean functional brain responses at baseline, single dose, and steady state for the escitalopram group.** Results of a one-sample *t*-test of the escitalopram group, revealing mean activation clusters. Results significant at  $p < 0.001$  cluster forming threshold corrected with  $p < 0.05$  FWE.

Brain Region	$p(\text{FWE-corr})$	Cluster Size	T	Z	MNI (x,y,z)
<i>Baseline</i>					
Right Paracentral Lobule	<0.001	2774	6.42	4.99	9, -43, 74
			6.27	4.91	18, 2, 59
			6.18	4.87	-9, -49, 68
Right Thalamus	0.012	169	6.39	4.98	12, -25, 17
			5.6	4.55	21, -34, 14
			4	3.53	27, -49, 2
Left Cerebellum	<0.001	437	5.72	4.62	-42, -55, -34
			5.14	4.27	-36, -58, -52
			4.92	4.14	-33, -67, -49
Right Middle Temporal Gyrus	<0.001	478	5.68	4.6	48, -43, 5
			4.89	4.12	51, -46, 26
			4.81	4.07	51, -28, -4
Right Cerebellum	0.007	193	4.88	4.12	30, -40, -40
			4.53	3.89	30, -58, -34
			4.47	3.85	36, -52, -52
<i>Single Dose</i>					
Left Premotor Cortex	<0.001	14076	9.93	6.45	-24, 2, 62
			9.84	6.42	6, -52, 56
			9.62	6.34	-9, -49, 62
Right Cerebellum	<0.001	336	6.18	4.87	30, -67, -25
			6.05	4.8	36, -52, -49
			5.37	4.41	39, -58, -28
<i>Steady State</i>					
Right Postcentral Gyrus	<0.001	530	6.93	5.25	6, -49, 68
			6.05	4.8	-12, -49, 71
			4.54	3.9	-18, -64, 59
Right Middle Frontal Gyrus	0.031	137	5.88	4.71	30, 2, 65
			5.49	4.49	24, -1, 71
			4.35	3.77	-6, -4, 77
Left Cerebellum	0.001	310	5.78	4.65	-36, -49, -37
			5.38	4.42	-39, -58, -31
			4.86	4.11	-33, -70, -19

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

**Supplementary Table 2. Mean functional brain responses at baseline, single dose, and steady state for the placebo group.** Results of a one-sample *t*-test of the placebo group, revealing mean activation clusters. Results significant at  $p < 0.001$  cluster forming threshold corrected with  $p < 0.05$  FWE.

Brain Region	$p$ (FWE-corr)	Cluster Size	T	Z	MNI (x,y,z)
<i>Baseline</i>					
Left Cerebellum	<0.001	8893	9.74	6.49	-36, -55, -49
			9.08	6.25	-24, -1, 65
			8.43	5.99	6, -52, 65
Right Cerebellum	0.001	198	7.05	5.37	30, -64, -52
			6.76	5.23	33, -52, -52
			6.57	5.13	27, -46, -46
Right Superior Temporal Gyrus	<0.001	1007	6.95	5.32	48, -28, 2
			6.86	5.28	51, -34, 8
			6.29	4.99	48, -37, 29
<i>Single Dose</i>					
Left Supp. Motor Area	<0.001	2646	7.82	5.73	-6, -1, 65
			6.63	5.16	24, 2, 65
			6.59	5.14	-24, 2, 68
Left Precuneus	<0.001	1010	7.52	5.59	-9, -58, 59
			6.96	5.33	6, -46, 74
			6.47	5.08	9, -52, 68
Right Cerebellum	0.03	102	7.51	5.59	30, -64, -49
			4.77	4.08	36, -49, -49
			4.48	3.89	30, -43, -46
Left Cerebellum	<0.001	363	6.18	4.93	-39, -58, -31
			5.39	4.48	-30, -67, -25
			5.17	4.34	-36, -55, -43
Right Cerebellum	0.009	141	5.77	4.7	33, -64, -28
			4.43	3.86	36, -49, -37
			3.57	3.23	51, -64, -28
Right Superior Temporal Gyrus	0.001	244	5.72	4.67	60, -40, 23
			5.05	4.26	48, -40, 2
			3.62	3.27	48, -31, -1
<i>Steady State</i>					
Left Postcentral Gyrus	<0.001	532	6.3	4.99	-9, -52, 65
			5.91	4.77	15, -61, 65
			5.26	4.39	-12, -61, 53
Left Premotor Cortex	0.001	251	6.21	4.94	-21, -1, 59
			5.6	4.6	-18, -1, 74
			4.51	3.91	-3, 5, 65
Right Middle Frontal Gyrus	0.007	168	5.75	4.68	30, 2, 65
			5.1	4.29	24, 2, 50
			4.51	3.91	18, 8, 62

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

**Supplementary Table 3. Significant correlations of brain and behavior – Escitalopram**

**Group:** Brain regions showing significant positive correlations between decreases in the learning contrast and improvements in lag learning-simple scores (LLSS) in the escitalopram group (n=29), KE=cluster size, T=t-values, Z=z-values, MNI(x,y,z)=MNI peak coordinates.

Brain Region	<i>p</i> (FWE-corr)	Cluster Size	T	Z	MNI (x,y,z)
Left Premotor Cortex	<0.001	368	6.37	5.15	-18, -4, 56
			5.16	4.47	-18, 14, 53
			5.43	4.45	-9, 11, 68
Left Middle Temporal Gyrus	<0.001	373	5.70	4.61	-45, -64, -1
			5.13	4.27	-42, -79, 20
			4.69	4.21	-42, -55, 11
Left Middle Temporal Gyrus	<0.001	307	5.55	4.52	51, -55, -7
			4.86	4.11	39, -67, 26
			4.56	3.91	39, -55, 11
Left Postcentral Gyrus	<0.001	346	5.43	4.45	-12, -52, 59
			5.03	4.21	-6, -58, 65
			4.53	3.89	-15, -61, 53
Right Precentral Gyrus	0.032	83	5.33	4.39	-54, 8, 32
			4.78	4.05	-54, 2, 38
			4.42	3.82	-42, -1, 26
Left Superior Frontal Gyrus	0.002	160	5.09	4.25	-12, -19, 41
			4.72	4.02	-6, -25, 53
			4.29	3.73	-12, -22, 59
Left Middle Frontal Gyrus	<0.001	338	4.86	4.11	-30, 44, 32
			4.62	3.95	-27, 53, 20
			4:60	3.94	-6, 41, 26
Left Thalamus	0.001	166	4.78	4.05	-18, -13, 14
			4.18	3.66	-27, -34, -4
			4.14	3.62	-18, -34, 19
Left Superior Parietal Lobule	0.048	74	4.78	4.05	-42, -43, 56
			3.98	3.51	-33, -43, 32
			3.78	3.37	-39, -46, 41

**Running Head:** Premotor cortex response to motor learning during escitalopram-intake

**Supplementary Table 4. Significant correlations of cortical motor response during sequence specific learning with drug plasma levels – Escitalopram Group:** Brain regions showing significant negative correlations between decreases in the learning contrast and increases in escitalopram plasma levels, KE=cluster size, T=*t*-values, Z=*z*-values, MNI(x,y,z)=MNI peak coordinates.

Brain Region	<i>p</i> (FWE-corr)	Cluster Size	T	Z	MNI (x,y,z)
Left Supramarginal Gyrus	0.002	164	5.87	4.70	-33, -40, 32
			5.15	4.29	-33, -43, 41
			4.26	3.71	-45, -40, 50
Right Posterior Somatosensory Cortex	<0.001	311	5.5	4.49	21, -55, 44
			5.31	4.38	33, -55, 26
			5.2	4.31	18, -61, 50
Left Premotor Cortex	<0.001	198	4.9	4.13	-9, 11, 68
			4.74	4.03	-21, -4, 68
			4.69	4.00	-18, -4, 56